2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156908
    3-OH-Kynurenamine 99362-47-7 98%
    3-OH-Kynurenamine is a lateral metabolite in Tryptophan (HY-N0623) metabolism. 3-OH-Kynurenamine induces a concentration-dependent AhR activation, around 6.5 times higher than L-kynurenine (HY-104026). 3-OH-Kynurenamine confers immunosuppressive properties on dendritic cells (DCs). 3-OH-Kynurenamine can be used for psoriasis research.
    3-OH-Kynurenamine
  • HY-156915
    Pim-1 kinase inhibitor 13 79492-49-2 98%
    Pim-1 Kinase Inhibitor 13 (compound 10) is a Pim-1 kinase inhibitor with an IC50 of 4.41 μM. Pim-1 Kinase Inhibitor 13 can be utilized in immunology or cancer research.
    Pim-1 kinase inhibitor 13
  • HY-15691A
    PF-4455242 hydrochloride 1322001-35-3 98%
    PF-4455242 hydrochloride is a selective, short-acting antagonist of the κ-opioid receptor, exhibiting potential analgesic effects. PF-4455242 hydrochloride has been identified through a strategy utilizing parallel chemistry and physicochemical property design. PF-4455242 hydrochloride demonstrated confirmed potency and selectivity in the tail-flick analgesia model.
    PF-4455242 hydrochloride
  • HY-156920
    VDX-111 158983-23-4 98%
    VDX-111 is an analog of vitamin D. VDX-111 exhibits cytotoxicity in ovarian cancer cells through upregulation of RIPK1/RIPK3 pathway and induction of necroptosis. VDX-111 promotes expressions of cytokines and exhibits antitumor activity in mouse model.
    VDX-111
  • HY-156958
    S-72 2446799-14-8 98%
    S-72 inhibits tubulin polymerization and further triggers mitosis-phase cell cycle arrest and cell apoptosis, in addition to suppressing STAT3 signaling.
    S-72
  • HY-156960
    JNJ-40929837 1191044-42-4 98%
    JNJ-40929837 is a selective and orally active LTA4H (leukotriene A4 hydrolase) inhibitor. JNJ-40929837 effectively inhibits aminopeptidase activity and causes serum accumulation of Pro-Gly-Pro. JNJ-40929837 can be used in asthma research.
    JNJ-40929837
  • HY-156973
    Tiopropamine 39516-21-7 98%
    Tiopropamine is an anti-inflammatory agent, with potential effect on histamine receptor.
    Tiopropamine
  • HY-15698B
    CRT0066101 trihydrochloride 1781742-22-0 98%
    CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2 with an IC50 of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects.
    CRT0066101 trihydrochloride
  • HY-156996
    AGI-134 1821461-84-0 98%
    AGI-134 is a fully synthetic alpha-Gal glycolipid. AGI-134 invokes CD8+ T cell-mediated immunity. AGI-134 induces tumor cell destruction and phagocytosis.
    AGI-134
  • HY-157011
    JAK-IN-33 3032404-49-9 98%
    JAK-IN-33 (compound 3 (R)) is a JAK inhibitor.
    JAK-IN-33
  • HY-157021
    SARS-CoV-2-IN-66 1807620-38-7 98%
    SARS-CoV-2-IN-66 (1), a vitaminK derivative, is a SARS-CoV-2 inhibitor, with an EC50 of 70.8 μM in VeroE6/TMPRSS2 cells.
    SARS-CoV-2-IN-66
  • HY-157033
    LMP7-IN-2 1613317-24-0 98%
    LMP7-IN-2 is a LMP7 inhibitor. LMP7-IN-2 can be used for associated inflammatory diseases and disorders.
    LMP7-IN-2
  • HY-157038
    MAGL-IN-8 3017151-71-9 98%
    MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC50 of 2.5 ± 0.4 nM for hMAGL.
    MAGL-IN-8
  • HY-157121
    JAK-IN-34 2068766-90-3 98%
    JAK-IN-34 (compound 11n) is a potent against of JAKs with IC50 values of 0.40, 0.83, 2.10, 1.95 nM target JAK1, JAK2, JAK3, TYK2, respectively. JAK-IN-34 reduces joint swelling with good safety.
    JAK-IN-34
  • HY-157128
    PI3Kδ-IN-18 3019965-38-6 98%
    Se15 is a selective inhibitor of PI3Kδ with an IC50 value less than 0.1nM. Se15 can be used in research on autoimmune.
    PI3Kδ-IN-18
  • HY-157139
    ALP/Carbonic anhydrase-IN-1 2091887-74-8 99.90%
    ALP/Carbonic anhydrase-IN-1 (Compound 1e) is a dual carbonic anhydrase (CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonic anhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively.
    ALP/Carbonic anhydrase-IN-1
  • HY-157146
    NLRP3-IN-23 98%
    NLRP3-IN-23 (Compound 15C) is an inhibitor of heme-mediated induction of the NLRP3 inflammasome. NLRP3-IN-23 significantly inhibits heme-mediated induction of the NLRP3 inflammasome at a concentration of 0.1 μM.
    NLRP3-IN-23
  • HY-157147
    NLRP3-IN-24 98%
    NLRP3-IN-24 (Compounds 15a) is an inhibitor against NLRP3. NLRP3-IN-24 has an inhibitory effect on the activation of NLRP3 inflammasome.
    NLRP3-IN-24
  • HY-157153
    hDHODH-IN-14 881826-17-1 98%
    hDHODH-IN-14 (compound 14) is a human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC50 of 0.469 μM.
    hDHODH-IN-14
  • HY-157173
    Mannosamine-biotin adduct 98%
    Mannosamine–biotin adduct is a hapten. Mannosamine–biotin adduct conjugated to hsIgG significantly reduces antibody immune responses against hsIgG.
    Mannosamine-biotin adduct
Cat. No. Product Name / Synonyms Application Reactivity